Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis

verfasst von: Jie Mei, Hai-Xia Duan, Ling-Ling Wang, Sen Yang, Jie-Qiang Lu, Ting-Yan Shi, Yu Zhao

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

X-ray repair cross complementing 1 (XRCC1) plays a key role in DNA repair, genetic instability and tumorigenesis. A series of epidemiological studies have examined associations between XRCC1 polymorphisms and cervical cancer risk, but the findings remain inconclusive. We searched three electronic databases (MEDLINE, EMBASE and CNKI) for studies on the association between XRCC1 polymorphisms and cervical cancer risk published before June 2013. Pooled odds ratio (OR) and 95 % confidence interval (CI) were calculated to estimate risk associations. A total of 28 case–control studies from 15 publications with 5,890 cervical cancer cases and 7,626 controls were identified. There was a significant association between rs25487 and cervical cancer risk in Asian populations (Dominant model: OR = 1.25, 95 % CI =1.04–1.50, P = 0.051 for heterogeneity test). After excluding three studies deviated from Hardy–Weinberg equilibrium, we observed a significant association of rs1799782 with cervical cancer risk in all populations and in Asian populations (Recessive model: OR = 1.62 and 1.72, 95 % CI = 1.22–2.14 and 1.29–2.30, P = 0.090 and 0.266 for heterogeneity test, respectively). However, there was no significant association between rs25489 and cervical cancer risk. These findings were further confirmed by false-positive report probability analysis. No publication bias was found by using the funnel plot and Egger's test. This meta-analysis provides strongly statistical evidence for the association between rs1799782 and cervical cancer risk, as well as its association with rs25487 only in Asian populations. However, single large, well-designed prospective studies are needed to confirm these findings.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef
3.
Zurück zum Zitat Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol. 2000;18:2309–15.PubMed Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol. 2000;18:2309–15.PubMed
4.
Zurück zum Zitat Han SS, Kim JW, Lee SH, Kim DH, Park NH, Song YS, et al. ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women. Asia Pac J Clin Oncol. 2012;8:e63–7.PubMedCrossRef Han SS, Kim JW, Lee SH, Kim DH, Park NH, Song YS, et al. ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women. Asia Pac J Clin Oncol. 2012;8:e63–7.PubMedCrossRef
5.
Zurück zum Zitat Alsbeih G, Al-Harbi N, El-Sebaie M, Al-Badawi I. HPV prevalence and genetic predisposition to cervical cancer in saudi arabia. Infect Agent Cancer. 2013;8:15.PubMedCentralPubMedCrossRef Alsbeih G, Al-Harbi N, El-Sebaie M, Al-Badawi I. HPV prevalence and genetic predisposition to cervical cancer in saudi arabia. Infect Agent Cancer. 2013;8:15.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Almeida KH, Sobol RW. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst). 2007;6:695–711.CrossRef Almeida KH, Sobol RW. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst). 2007;6:695–711.CrossRef
7.
Zurück zum Zitat Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Asp Med. 2007;28:258–75.CrossRef Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Asp Med. 2007;28:258–75.CrossRef
8.
Zurück zum Zitat Lamerdin JE, Montgomery MA, Stilwagen SA, Scheidecker LK, Tebbs RS, Brookman KW, et al. Genomic sequence comparison of the human and mouse xrcc1 DNA repair gene regions. Genomics. 1995;25:547–54.PubMedCrossRef Lamerdin JE, Montgomery MA, Stilwagen SA, Scheidecker LK, Tebbs RS, Brookman KW, et al. Genomic sequence comparison of the human and mouse xrcc1 DNA repair gene regions. Genomics. 1995;25:547–54.PubMedCrossRef
9.
Zurück zum Zitat Barbisan G, Perez LO, Difranza L, Fernandez CJ, Ciancio NE, Golijow CD. XRCC1 Arg399Gln polymorphism and risk for cervical cancer development in Argentine women. Eur J Gynaecol Oncol. 2011;32:274–9.PubMed Barbisan G, Perez LO, Difranza L, Fernandez CJ, Ciancio NE, Golijow CD. XRCC1 Arg399Gln polymorphism and risk for cervical cancer development in Argentine women. Eur J Gynaecol Oncol. 2011;32:274–9.PubMed
10.
Zurück zum Zitat Djansugurova LB, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM. The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan. Front Genet. 2013;4:70.PubMedCentralPubMedCrossRef Djansugurova LB, Perfilyeva AV, Zhunusova GS, Djantaeva KB, Iksan OA, Khussainova EM. The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan. Front Genet. 2013;4:70.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Farkasova T, Gurska S, Witkovsky V, Gabelova A. Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients; a pilot study. Neoplasma. 2008;55:330–7.PubMed Farkasova T, Gurska S, Witkovsky V, Gabelova A. Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients; a pilot study. Neoplasma. 2008;55:330–7.PubMed
12.
Zurück zum Zitat Huang J, Ye F, Chen H, Lu W, Xie X. The nonsynonymous single nucleotide polymorphisms of DNA repair gene XRCC1 and susceptibility to the development of cervical carcinoma and high-risk human papillomavirus infection. Int J Gynecol Cancer. 2007;17:668–75.PubMedCrossRef Huang J, Ye F, Chen H, Lu W, Xie X. The nonsynonymous single nucleotide polymorphisms of DNA repair gene XRCC1 and susceptibility to the development of cervical carcinoma and high-risk human papillomavirus infection. Int J Gynecol Cancer. 2007;17:668–75.PubMedCrossRef
13.
Zurück zum Zitat Jiang W, Wang ML, Zhang ZZ, Chen XJ, Zhu H, Qian NF, et al. The relationship between XRCC1 polymorphisms and the risk of cervical cancer in Jiangsu population [in chinese]. Acta Univ Med Nanjing (Nat Sci). 2008;28:1–6. Jiang W, Wang ML, Zhang ZZ, Chen XJ, Zhu H, Qian NF, et al. The relationship between XRCC1 polymorphisms and the risk of cervical cancer in Jiangsu population [in chinese]. Acta Univ Med Nanjing (Nat Sci). 2008;28:1–6.
14.
Zurück zum Zitat MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ. Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet. 2011;27:141–8.PubMedCentralPubMedCrossRef MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ. Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet. 2011;27:141–8.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Niwa Y, Matsuo K, Ito H, Hirose K, Tajima K, Nakanishi T, et al. Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects. Gynecol Oncol. 2005;99:43–9.PubMedCrossRef Niwa Y, Matsuo K, Ito H, Hirose K, Tajima K, Nakanishi T, et al. Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects. Gynecol Oncol. 2005;99:43–9.PubMedCrossRef
16.
Zurück zum Zitat Roszak A, Lianeri M, Jagodzinski PP. Involvement of the XRCC1 Arg399Gln gene polymorphism in the development of cervical carcinoma. Int J Biol Markers. 2011;26:216–20.PubMed Roszak A, Lianeri M, Jagodzinski PP. Involvement of the XRCC1 Arg399Gln gene polymorphism in the development of cervical carcinoma. Int J Biol Markers. 2011;26:216–20.PubMed
17.
Zurück zum Zitat Settheetham-Ishida W, Yuenyao P, Natphopsuk S, Settheetham D, Ishida T. Genetic risk of DNA repair gene polymorphisms (XRCC1 and XRCC3) for high risk human papillomavirus negative cervical cancer in northeast Thailand. Asian Pac J Cancer Prev. 2011;12:963–6.PubMed Settheetham-Ishida W, Yuenyao P, Natphopsuk S, Settheetham D, Ishida T. Genetic risk of DNA repair gene polymorphisms (XRCC1 and XRCC3) for high risk human papillomavirus negative cervical cancer in northeast Thailand. Asian Pac J Cancer Prev. 2011;12:963–6.PubMed
18.
Zurück zum Zitat Wang SS, Bratti MC, Rodriguez AC, Herrero R, Burk RD, Porras C, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009;199:20–30.PubMedCentralPubMedCrossRef Wang SS, Bratti MC, Rodriguez AC, Herrero R, Burk RD, Porras C, et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis. 2009;199:20–30.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Wu MT, Chen SY, Wu TN, Hwang HY, Ho CK, Lee LH, et al. No association between polymorphisms of the DNA repair gene XRCC1 and cervical neoplasm risk. Environ Health Prev Med. 2003;8:100–3.PubMedCentralPubMedCrossRef Wu MT, Chen SY, Wu TN, Hwang HY, Ho CK, Lee LH, et al. No association between polymorphisms of the DNA repair gene XRCC1 and cervical neoplasm risk. Environ Health Prev Med. 2003;8:100–3.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Xiao H, Wu W, Xie H, Bao X. Relationship between the polymorphism of XRCC-Arg399Gln and incidence risk of cervical cancer in the population of Guangdong [in Chinese]. Hainan Med J. 2010;21:35–7. Xiao H, Wu W, Xie H, Bao X. Relationship between the polymorphism of XRCC-Arg399Gln and incidence risk of cervical cancer in the population of Guangdong [in Chinese]. Hainan Med J. 2010;21:35–7.
21.
Zurück zum Zitat Zhang L, Ruan Z, Hong Q, Gong X, Hu Z, Huang Y, et al. Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: a case–control study. Oncol Lett. 2012;3:351–62.PubMedCentralPubMed Zhang L, Ruan Z, Hong Q, Gong X, Hu Z, Huang Y, et al. Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: a case–control study. Oncol Lett. 2012;3:351–62.PubMedCentralPubMed
22.
Zurück zum Zitat Wang X, Yang Z. The association between XRCC1 polymorphisms and cervical cancer risk [in Chinese]. Mod Med Health. 2010;26:2137–8. Wang X, Yang Z. The association between XRCC1 polymorphisms and cervical cancer risk [in Chinese]. Mod Med Health. 2010;26:2137–8.
23.
Zurück zum Zitat Ma W, Jin P, Guo Y. Single nucleotide polymorphisms of the DNA repair genes XPD and XRCC1 and the susceptibility to cervical squamous cell carcinoma [in Chinese]. Prog Obstet Gynecol. 2011;20:881–5. Ma W, Jin P, Guo Y. Single nucleotide polymorphisms of the DNA repair genes XPD and XRCC1 and the susceptibility to cervical squamous cell carcinoma [in Chinese]. Prog Obstet Gynecol. 2011;20:881–5.
24.
Zurück zum Zitat Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
25.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
26.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
27.
Zurück zum Zitat Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
28.
Zurück zum Zitat Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef
29.
Zurück zum Zitat Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–42.PubMedCrossRef Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–42.PubMedCrossRef
30.
Zurück zum Zitat Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 2008;111:509–15.PubMedCrossRef Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 2008;111:509–15.PubMedCrossRef
31.
Zurück zum Zitat Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB, et al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol. 2006;103:1031–7.PubMedCrossRef Chung HH, Kim MK, Kim JW, Park NH, Song YS, Kang SB, et al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol. 2006;103:1031–7.PubMedCrossRef
32.
Zurück zum Zitat Cheng XD, Lu WG, Ye F, Wan XY, Xie X. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res. 2009;28:91.PubMedCrossRef Cheng XD, Lu WG, Ye F, Wan XY, Xie X. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res. 2009;28:91.PubMedCrossRef
33.
Zurück zum Zitat Encheva E, Yordanova I, Lakov T, Savov A, Kremensky I, Mitev V, et al. Genetic, clinical and environmental factors with a probable role for development of early radiation adverse events in cervical and endometrial cancer patients after postoperative pelvic irradiation. Rentgenol Radiol. 2011;50:190–6. Encheva E, Yordanova I, Lakov T, Savov A, Kremensky I, Mitev V, et al. Genetic, clinical and environmental factors with a probable role for development of early radiation adverse events in cervical and endometrial cancer patients after postoperative pelvic irradiation. Rentgenol Radiol. 2011;50:190–6.
34.
Zurück zum Zitat De Ruyck K, Wilding CS, Van Eijkeren M, Morthier R, Tawn EJ, Thierens H. Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: association with late clinical radiosensitivity and cancer incidence. Radiat Res. 2005;164:237–44.PubMedCrossRef De Ruyck K, Wilding CS, Van Eijkeren M, Morthier R, Tawn EJ, Thierens H. Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: association with late clinical radiosensitivity and cancer incidence. Radiat Res. 2005;164:237–44.PubMedCrossRef
35.
Zurück zum Zitat De Ruyck K, Van Eijkeren M, Claes K, Morthier R, De Paepe A, Vral A, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC 3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys. 2005;62:1140–9.PubMedCrossRef De Ruyck K, Van Eijkeren M, Claes K, Morthier R, De Paepe A, Vral A, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: Association with single nucleotide polymorphisms in XRCC1, XRCC 3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys. 2005;62:1140–9.PubMedCrossRef
36.
Zurück zum Zitat Hong Q. Association of ADPRT and XRCC1 gene polymorphisms with susceptibility to squamous cell carcinoma of cervix [in Chinese]: Obstetrics and Gynecology. Shanghai, Fudan University, 2008, Master, pp 56. Hong Q. Association of ADPRT and XRCC1 gene polymorphisms with susceptibility to squamous cell carcinoma of cervix [in Chinese]: Obstetrics and Gynecology. Shanghai, Fudan University, 2008, Master, pp 56.
37.
Zurück zum Zitat Wu MT, Liu CL, Ho CK, Wu TN. Genetic polymorphism of p53 and XRCC1 in cervical intraepithelial neoplasm in Taiwanese women. J Formos Med Assoc. 2004;103:337–43.PubMed Wu MT, Liu CL, Ho CK, Wu TN. Genetic polymorphism of p53 and XRCC1 in cervical intraepithelial neoplasm in Taiwanese women. J Formos Med Assoc. 2004;103:337–43.PubMed
38.
Zurück zum Zitat Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33:177–82.PubMedCrossRef Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33:177–82.PubMedCrossRef
39.
Zurück zum Zitat Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a huge review. Am J Epidemiol. 2006;164:297–302.PubMedCrossRef Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a huge review. Am J Epidemiol. 2006;164:297–302.PubMedCrossRef
40.
Zurück zum Zitat Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, et al. Xrcc1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001;104:107–17.PubMedCrossRef Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, et al. Xrcc1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001;104:107–17.PubMedCrossRef
41.
Zurück zum Zitat Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol. 2002;22:2556–63.PubMedCentralPubMedCrossRef Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol. 2002;22:2556–63.PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat Li Y, Liu F, Tan SQ, Wang Y, Li SW. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and cervical cancer risk: a huge systematic review and meta-analysis. PLoS One. 2012;7:e44441.PubMedCentralPubMedCrossRef Li Y, Liu F, Tan SQ, Wang Y, Li SW. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and cervical cancer risk: a huge systematic review and meta-analysis. PLoS One. 2012;7:e44441.PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Shuai HL, Luo X, Yan RL, Li J, Chen DL. XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:6423–7.PubMedCrossRef Shuai HL, Luo X, Yan RL, Li J, Chen DL. XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:6423–7.PubMedCrossRef
44.
Zurück zum Zitat Liu YT, Shi JP, Fu LY, Zhou B, Wang HL, Wu XM. Gene polymorphism of XRCC1 Arg399Gln and cervical carcinoma susceptibility in Asians: a meta-analysis based on 1,759 cases and 2,497 controls. Asian Pac J Cancer Prev. 2013;14:189–93.PubMedCrossRef Liu YT, Shi JP, Fu LY, Zhou B, Wang HL, Wu XM. Gene polymorphism of XRCC1 Arg399Gln and cervical carcinoma susceptibility in Asians: a meta-analysis based on 1,759 cases and 2,497 controls. Asian Pac J Cancer Prev. 2013;14:189–93.PubMedCrossRef
45.
Zurück zum Zitat Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7:781–91.PubMedCrossRef Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7:781–91.PubMedCrossRef
Metadaten
Titel
XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis
verfasst von
Jie Mei
Hai-Xia Duan
Ling-Ling Wang
Sen Yang
Jie-Qiang Lu
Ting-Yan Shi
Yu Zhao
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1163-7

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.